The Latest Breaking News from AstraZeneca

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Scrapping top rate of tax could save hundreds of thousands for some of the highest earners, analysis reveals

AstraZeneca is supporting the work the Trust does across the Lanarkshire community.

Wall Street Journal

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

The drug reduces the risk of death by 20% compared with chemotherapy alone

Regulators in Australia and the United States last week approved Omicron-specific boosters, following approval in the United Kingdom in mid-August.

A jump in the number of deaths among children in Europe could be caused by numerous factors, experts said, but vaccines are not to blame.

The company first developed the drug as a treatment for type-2 diabetes 

Upgrades